Editorial: Targeting circulatory dysfunction in cirrhosis: Terlipressin and the hepatorenal syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 11, 2009, Pages 1707-1709

  Testro, Adam G ^a   Angus, Peter W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN; TERLIPRESSIN; DRUG DERIVATIVE; LYPRESSIN; VASOCONSTRICTOR AGENT;

ARTERY RESISTANCE; BLOOD VESSEL TONE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; EDITORIAL; HEART OUTPUT; HEART RATE; HEPATORENAL SYNDROME; HUMAN; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER ISCHEMIA; MEAN ARTERIAL PRESSURE; NORADRENALIN BLOOD LEVEL; OVERALL SURVIVAL; PLASMA RENIN ACTIVITY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMIC VASCULAR RESISTANCE; VENOUS PRESSURE; DRUG EFFECT; HEMODYNAMICS; KIDNEY CIRCULATION; LIVER CIRCULATION; NOTE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; LYPRESSIN; RENAL CIRCULATION; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 70449382626     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06034.x     Document Type: Editorial

References (24)

1. Ryckwaert F, Virsolvy A, Fort A et al. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit. Care Med. 2009 37 : 876 881.
2. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp. Clin. Res. 1990 16 : 307 314.
3. Hirasawa A, Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commun. 1994 203 : 72 9.
4. Narahara Y, Kanazawah H, Taki Y et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J. Gastroenterol. Hepatol. 2009 24 : 1791 1797.
5. Wan L, Yang N, Hiew CY et al. An assessment of the accuracy of renal blood flow estimation by Doppler ultrasound. Intensive Care Med. 2008 34 : 1503 1510.
6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988 8 : 1151 1157.
7. Albornoz L, Motta A, Alvarez D et al. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J. Hepatol. 2001 35 : 452 456.
8. Solis-Herruzo JA, Duran A, Favela V et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J. Hepatol. 1987 5 : 167 173.
9. Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005 42 : 439 447.
10. Ruiz-del-Arbol L, Urman J, Fernandez J et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003 38 : 1210 1218.
11. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006 43 : 385 394.
12. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007 56 : 1310 1318. (Pubitemid 47300435)
13. Sanyal AJ, Boyer T, Garcia-Tsao G et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008 134 : 1360 1368.
14. Martin-Llahi M, Pepin MN, Guevara M et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008 134 : 1352 1359.
15. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000 33 : 43 8.
16. Colle I, Durand F, Pessione F et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J. Gastroenterol. Hepatol. 2002 17 : 882 888.
17. Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J. Gastroenterol. Hepatol. 2008 23 : 1535 1540.
18. Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischemic complications of Glypressin in liver disease: a case series. Br. J. Clin. Pharmacol. 2007 64 : 550 552.
19. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst. Rev. 2003 (1 CD002147.
20. Abid S, Jafri W, Hamid S et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am. J. Gastroenterol. 2009 104 : 617 623.
21. Baik SK, Jeong PH, Ji SW et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am. J. Gastroenterol. 2005 100 : 631 635.
22. Escorsell A, Bandi JC, Andreu V et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001 120 : 161 169.
23. Connolly M, Bhatt A, Wechowski J, Colle I. An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastroenterol. Belg. 2008 71 : 230 236.
24. Wechowski J, Connolly M, Woehl A et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr. Med. Res. Opin. 2007 23 : 1481 1491.